Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetic Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetic Technologies's position in the market.
Genetic Technologies Limited (NASDAQ: GENE) announced it has met the Nasdaq minimum stockholders' equity requirement of $2.5 million, as confirmed by the Listing Qualifications Department. The company raised $16.37 million since April 2020 through offerings of American Depositary Shares, resulting in US GAAP stockholders' equity exceeding $2.5 million as of August 28, 2020. Consequently, GENE's shares will continue listing on The Nasdaq Capital Market.